Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
KENILWORTH (NJ) (dpa-AFX) - Japans Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) announced Tuesday positive topline results from…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash., July 26, 2022 /PRNewswire/ -- Astellas…
New 154,000-square-foot facility will provide a West Coast center with a focus on research, innovation, and commercial collaboration across corporate…
Mogrify has developed a suite of platform technologies that use a systematic big-data approach for direct cellular reprogramming and to…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Mogrify Limited and Astellas Pharma Inc. (ALPMY, ALPMY) have executed a collaborative research agreement on in vivo…
CAMBRIDGE, United Kingdom and TOKYO, July 5, 2022 /PRNewswire/ -- Mogrify Limited (CEO: Darrin M. Disley, Ph.D., "Mogrify®"), a biopharmaceutical…
As part of the collaboration, both the companies will conduct research and preclinical development activities together for identifying new monovalent…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
PITTSBURGH and CAMBRIDGE, Mass. , June 29, 2022 /PRNewswire/ -- Generian Pharmaceuticals, Inc. ("Generian") and Mitobridge, Inc. (a wholly owned…
Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients…
Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BEIJING (dpa-AFX) - Astellas Pharma Inc. and Sutro Biopharma Inc. (STRO) announced a worldwide, strategic collaboration and licensing agreement focused…
Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas...…
- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for…
- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOKYO, June 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that…
TOKYO (dpa-AFX) - Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food…
Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas…
DUBLIN, June 21, 2022 /PRNewswire/ -- The "Stem Cell Therapy Global Market Report 2022: By Type, By Cell, By Application,…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
NEW YORK, June 1, 2022 /PRNewswire/ -- The "Interstitial Cystitis Drugs Market by Type (Oral therapy and Intravesical therapy) and…
- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc.…
Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ --…
Astellas investigational nonhormonal treatment meets all primary endpoints, significantly reducing the frequency and severity of vasomotor symptoms associated with menopause…
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) reported that its fiscal 2021 core operating profit decreased by 2.6% year-on-year…
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the company and the University of Tokyo have entered the second…
TOKYO, April 25, 2022 /PRNewswire/ -- The University of Tokyo (President: Teruo Fujii, Ph.D.) and Astellas Pharma Inc. (TSE: 4503,…
NEW YORK, April 20, 2022 /PRNewswire/ -- The global non-small cell lung cancer drugs market size is expected to increase…
- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and…
Turn Biotechnologies, Inc.: Mountain View, Kalifornien (ots/PRNewswire) - Daewoong Pharmaceutical und HanAll Biopharma beteiligen sich gemeinsam mit Astellas Venture Management…
GRENOBLE, Frankreich--(BUSINESS WIRE)--CYTOO und Astellas Gene Therapies (AGT) sind im Jahr 2020 eine Forschungskooperation eingegangen, um den klinischen AAV-Gentherapie-Kandidaten von…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that 12-week data from phase 3 MOONLIGHT 1 study of fezolinetant…
Astellas MOONLIGHT 1TM clinical trial evaluating investigational fezolinetant 30 mg administered once daily TOKYO, March 14, 2022 /PRNewswire/ -- Astellas…
NEW YORK, March 14, 2022 /PRNewswire/ -- The central nervous system (CNS) stimulant drugs market is fragmented and the vendors…
NEW YORK, March 10, 2022 /PRNewswire/ -- Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOKYO, March 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
TOKYO and BOTHELL, Wash., Feb. 14, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas")…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive interim safety data from FORTIS Study. The Phase I/II clinical…
TOKYO, Feb. 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…